Earnings season has been a time when Valeant Pharmaceuticals NYSE VRX shareholders have played ostrich over the past year and a half and with good reason Last year Valeant wound up lowering its profit outlook and earnings before interest taxes depreciation and
May 09, 2017 at 05:10AM
from
No comments:
Post a Comment